Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01347294|
Recruitment Status : Unknown
Verified February 2017 by Rune Andersen, Oslo University Hospital.
Recruitment status was: Recruiting
First Posted : May 4, 2011
Last Update Posted : February 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Venous Malformation||Drug: Bleomycin Drug: Fibrovein Drug: Bleomycin + Fibrovein||Phase 4|
Patients with scanty symptoms from their vascular malformation can do well with conservative treatment and / or with aids and adaptations in daily life. Compression therapy (elastic stockings), pain medication and good counseling is adequate for many. Patients with significant symptoms, however, may require more invasive treatment. Previously, it was common with surgical removal, but serious sequelae and frequent recurrence after surgery resulted in caution. Today it is more common with intervention radiology treatment with injection of sclerosing agents into existing malformation. This type of therapy almost always requires repeated treatment sequences, sometimes over several months. Treatment aims to seal blood vessels in the malformation and / or make the patient as possible symptoms. Recurrence occurs frequently and there are many who are not completely free from symptoms. Many patients have chronic problems with pain, wounds, bleeding and / or they have a cosmetically disfiguring condition. Predicting the performance of a specific type of treatment can be very difficult.
Until now, there are some studies that have considered the effect of bleomycin / pingyangmycin (China) and ethanol in the treatment of vascular malformations. To our knowledge there is no prospective or retrospective studies that compare the efficacy and side effects of bleomycin and sodium tetradecyl sulfate (Fibrovein ™) in the treatment of VM.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||126 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations|
|Study Start Date :||August 2011|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
|Experimental: Bleomycin + Fibrovein||
Drug: Bleomycin + Fibrovein
Other Name: Bleomycin Baxter + Fibrovein pharmaceutical products
|Active Comparator: Bleomycin||
Other Name: Bleomycin Baxter
|Experimental: Natrium Tetradecyl Sulphate (Fibrovein )||
Other Name: Fibrovein S.T.D pharmaceutical products LTD
- Pain [ Time Frame: 1 year ]Pain will be measured before, during and after treatment. It will be asked about type, characteristics and intensity of pain. Using the VAS 0-10 will be used in this matter.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01347294
|Contact: Rune Andersen, firstname.lastname@example.org|
|Oslo Universitetssykehus Rikshospitalet||Recruiting|
|Oslo, Norway, 0227|
|Contact: Rune Andersen, MD +4723073992 email@example.com|
|Study Director:||Andreas Abildgaard, phd||Oslo Universitetssykehus, Rikshospitalet|